Active Ingredient History
Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie's disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. BioSpecifics Technologies developed the preparation, which is manufactured and marketed by Endo Pharmaceuticals as Xiaflex in the US and by Sobi as Xiapex in Europe. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anastomotic Leak (Early Phase 1)
Arterial Occlusive Diseases (Phase 1)
Burns (Phase 4)
Bursitis (Phase 2)
Cellulite (Phase 4)
Cicatrix (Phase 4)
Collagen (Early Phase 1)
Constriction, Pathologic (Early Phase 1)
Contracture (Phase 2)
Coronary Disease (Phase 2)
Dermatology (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetic Foot (Phase 4)
Esophageal Stenosis (Early Phase 1)
Fasciitis, Plantar (Phase 2)
Fibromatosis, Plantar (Phase 3)
Foot Ulcer (Phase 1)
Genital Diseases, Male (Phase 4)
Leiomyoma (Phase 1)
Lipoma (Phase 2)
Panniculitis (Phase 4)
Penis (Phase 4)
Peptic Ulcer (Phase 1)
Pressure Ulcer (Phase 4)
Sexual Dysfunctions, Psychological (Phase 4)
Tissue Adhesions (Phase 1/Phase 2)
Tissues (Phase 2)
Ulcer (Phase 2/Phase 3)
Urethral Stricture (Phase 2)
Wound Healing (Phase 4)
Wounds and Injuries (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
